The study was funded by Janssen Oncology. Access disclosures for Dr. Yu. Only patients with persistent EGFR in circulating tumor DNA (ctDNA) after initiating therapy with osimertinib are randomized to ...
together reinforce osimertinib as an effective, safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive Vice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback